U.S. Markets closed

Portage Biotech Inc. (PRTG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
18.58-0.72 (-3.73%)
At close: 4:00PM EDT
18.77 +0.19 (1.02%)
After hours: 05:35PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close19.30
Open18.83
Bid18.75 x 900
Ask19.11 x 900
Day's Range18.03 - 20.50
52 Week Range8.74 - 44.98
Volume16,292
Avg. Volume74,974
Market Cap224.51M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.50
  • GlobeNewswire

    Portage Biotech Announces Participation in September 2021 Investor Conferences

    WESTPORT, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that as part of its commitment to investor outreach, management will be participating in the following investor conferences in September 2021. H.C. Wainwright 23rd Annual Global Investor ConferenceDate: September 13, 2021Format: Co

  • GlobeNewswire

    Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year

    - $29 million raised during quarter with broad institutional support - Proceeds will accelerate advancement of clinical pipeline toward multiple data readouts over the next 18-24 months WESTPORT, Conn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced financial results for the quarter ended June 30

  • GlobeNewswire

    Portage Biotech Issues Letter to Shareholders

    WESTPORT, Conn., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today issued the following letter to shareholders: Dear Shareholders, On behalf of the team at Portage Biotech, Inc., I am pleased to provide you with a corporate update, reflecting on the progress that we have made throughout the first half of 2021 and the found